[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69233169D1 - Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor. - Google Patents

Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor.

Info

Publication number
DE69233169D1
DE69233169D1 DE69233169T DE69233169T DE69233169D1 DE 69233169 D1 DE69233169 D1 DE 69233169D1 DE 69233169 T DE69233169 T DE 69233169T DE 69233169 T DE69233169 T DE 69233169T DE 69233169 D1 DE69233169 D1 DE 69233169D1
Authority
DE
Germany
Prior art keywords
human
compound
tumor
topotecan
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69233169T
Other languages
English (en)
Other versions
DE69233169T2 (de
Inventor
Randall Keith Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of DE69233169D1 publication Critical patent/DE69233169D1/de
Publication of DE69233169T2 publication Critical patent/DE69233169T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69233169T 1991-11-15 1992-11-13 Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor. Expired - Lifetime DE69233169T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79304191A 1991-11-15 1991-11-15
US793041 1991-11-15
PCT/US1992/009864 WO1993009782A1 (en) 1991-11-15 1992-11-13 Combination chemotherapy

Publications (2)

Publication Number Publication Date
DE69233169D1 true DE69233169D1 (de) 2003-09-25
DE69233169T2 DE69233169T2 (de) 2004-05-27

Family

ID=25158913

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69233169T Expired - Lifetime DE69233169T2 (de) 1991-11-15 1992-11-13 Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor.

Country Status (15)

Country Link
US (1) US5633016A (de)
EP (3) EP0612248B1 (de)
JP (1) JPH07501079A (de)
AT (1) ATE247471T1 (de)
AU (1) AU671605B2 (de)
CA (1) CA2123321C (de)
DE (1) DE69233169T2 (de)
DK (1) DK0612248T3 (de)
ES (1) ES2204894T3 (de)
HK (1) HK1012268A1 (de)
MX (1) MX9206577A (de)
NZ (1) NZ245112A (de)
PT (1) PT101061B (de)
WO (1) WO1993009782A1 (de)
ZA (1) ZA928771B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
EP0612248B1 (de) * 1991-11-15 2003-08-20 Smithkline Beecham Corporation Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor.
EP0778024B1 (de) * 1993-01-15 2002-11-13 The Stehlin Foundation For Cancer Research Orale oder intramuskuläre Behandlung von Pankreaskrebs durch wasserunlösliches S-Camptothecin mit geschlossenem Lactonring
EP0715854B1 (de) 1994-11-11 2003-09-10 Debiopharm S.A. Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten
US6274576B1 (en) 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
CA2225682A1 (en) * 1995-06-27 1997-01-16 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
DK1044977T3 (da) * 1999-03-09 2002-07-08 Sigma Tau Ind Farmaceuti Camptothecinderivater med antitumoraktivitet
AU3755800A (en) * 1999-03-15 2000-10-04 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
EP1754488A1 (de) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten
EP2289549A3 (de) 1999-10-01 2011-06-15 Immunogen, Inc. Immunokonjugate für Krebsbehandlung
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
WO2001066144A2 (en) * 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
US6545010B2 (en) * 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
WO2002045737A2 (en) * 2000-12-07 2002-06-13 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
US20040009939A1 (en) * 2002-03-05 2004-01-15 Board Of Regent, The University Of Texas System Methods of enhancing immune induction involving MDA-7
EP2269619A1 (de) 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Verfahren und Zusammensetzungen in Bezug auf Pockenviren und Krebs
CA2518150C (en) * 2003-03-03 2015-08-11 Board Of Regents, The University Of Texas System Methods and compositions involving mda-7
CA2548220A1 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
CA2597329C (en) * 2005-02-08 2016-10-11 Board Of Regents, The University Of Texas System Compositions and methods involving mda-7 for the treatment of cancer
EP1888105A2 (de) * 2005-05-12 2008-02-20 Introgen Therapeutics, Inc. P53-impfstoffe zur krebsbehandlung
WO2007006019A1 (en) * 2005-07-06 2007-01-11 University Of South Florida Materials and methods for screening, diagnosis and prognosis of conditions associated with stat protein expression
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
KR20090004839A (ko) * 2005-09-07 2009-01-12 제네렉스, 인코포레이티드 Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
US20110028536A1 (en) * 2006-08-18 2011-02-03 Gjerset Ruth A Methods and compositions for topoisomerase i modulated tumor suppression
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
WO2009011861A1 (en) * 2007-07-16 2009-01-22 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
WO2009099651A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and cetuximab to treat colorectal cancer
WO2011032180A1 (en) 2009-09-14 2011-03-17 Jennerex, Inc. Oncolytic vaccinia virus combination cancer therapy
EP3327148B1 (de) 2010-06-18 2021-03-17 Myriad Genetics, Inc. Verfahren zur vorherbestimmung des status der gene brca1 und brca2 in einer krebszelle
WO2012027224A1 (en) 2010-08-24 2012-03-01 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
BR112013017096A2 (pt) 2011-01-04 2020-09-01 Jennerex Inc. composição e métodos de indução de resposta citotóxica dependente de complemento mediado por anticorpo específico de tumor em animal tendo tumor, de geração de anticorpos in vivo, de inibição do crescimento ou morte de célula de câncer, para tratar indivíduo com câncer, para adaptar de terapia de câncer para indivíduo com câncer e para identificar antígeno específico de tumor
JP6117194B2 (ja) 2011-06-17 2017-04-19 ミリアド・ジェネティックス・インコーポレイテッド アレル不均衡を評価するための方法および材料
WO2013094581A1 (ja) * 2011-12-21 2013-06-27 株式会社ヤクルト本社 新規なカンプトテシン誘導体
EP2794907B2 (de) 2011-12-21 2022-11-23 Myriad Genetics, Inc. Verfahren und materialien zur bewertung des verlusts der heterozygotie
CA3080441A1 (en) 2012-02-23 2013-09-06 The Children's Hospital Corporation Methods for predicting anti-cancer response
US11091808B2 (en) 2012-06-07 2021-08-17 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
PT2981624T (pt) 2013-04-05 2020-03-23 Myriad Genetics Inc Métodos para avaliar deficiência na recombinação homóloga e prever resposta a tratamento para cancro
US9821008B2 (en) * 2013-11-25 2017-11-21 The University Of Toledo Inhibitors of ERCC1-XPF and methods of using the same
EP4023765A1 (de) 2013-12-09 2022-07-06 Institut Curie Verfahren zum nachweis der inaktivierung des homologen rekombinationssignalwegs (brca1/2) bei menschlichen tumoren
EP3686288B1 (de) 2014-08-15 2023-03-08 Myriad Genetics, Inc. Verfahren und materialien zur beurteilung eines mangels an homologer rekombination
EP4141127B1 (de) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Verfahren zur bewertung des mangels an homologer rekombination in eierstockkrebszellen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS5839685A (ja) 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
NZ235329A (en) 1989-09-15 1992-01-29 Res Triangle Inst 20(s or rs)-camptothecin derivatives and pharmaceutical compositions
EP0612248B1 (de) * 1991-11-15 2003-08-20 Smithkline Beecham Corporation Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor.

Also Published As

Publication number Publication date
DK0612248T3 (da) 2003-12-08
MX9206577A (es) 1993-05-01
JPH07501079A (ja) 1995-02-02
CA2123321C (en) 2003-09-30
WO1993009782A1 (en) 1993-05-27
PT101061B (pt) 1999-07-30
HK1012268A1 (en) 1999-07-30
DE69233169T2 (de) 2004-05-27
US5633016A (en) 1997-05-27
CA2123321A1 (en) 1993-05-27
EP0612248A1 (de) 1994-08-31
ZA928771B (en) 1993-09-08
EP1393730A2 (de) 2004-03-03
ATE247471T1 (de) 2003-09-15
EP1393729A2 (de) 2004-03-03
AU671605B2 (en) 1996-09-05
AU3137993A (en) 1993-06-15
EP1393729A3 (de) 2004-03-17
EP0612248B1 (de) 2003-08-20
ES2204894T3 (es) 2004-05-01
PT101061A (pt) 1994-06-30
EP1393730A3 (de) 2004-03-17
EP0612248A4 (en) 1996-05-08
NZ245112A (en) 1995-07-26

Similar Documents

Publication Publication Date Title
DE69233169D1 (de) Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor.
DE69425661D1 (de) IMIDAZO [4,5-c]PYRIDIN-4-AMINE
EP0275005A3 (en) Complex compounds of bioflavonoids with phospholipids, their preparation and use, and pharmaceutical and cosmetic compositions containing them
IL104006A (en) Azaheterocyclylmethyl-chromans their preparation and pharmaceutical compositions containing them
EP0344880A3 (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer
GR3033253T3 (en) Tri(platinum) complexes
UA41285C2 (uk) Креатин фосфат і його фармацевтично прийнятні солі для лікування пухлин та фармацевтична композиція, що має протипухлинну активність
AU564439B2 (en) Pharmaceutical compositions containing l-alpha- glycerylphosphorylcholine
ATE476182T1 (de) Pharmazeutische zusammensetzung zur verwendung in der behandlung von eierstockkrebs
HK1012267A1 (en) Use of topotecan in the treatment of non-small cell lung carcinoma
IL106289A (en) Phospholipid derivatives their preparation and pharmaceutical compositions containing them
ATE87314T1 (de) Platin-arzneimittel.
MY105876A (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer.
GB8819626D0 (en) Pharmaceutical composition for treatment of tumours
AU2582588A (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer
PT1250926E (pt) Utilização de uma s-camptotecina insolúvel em água, com um anel de lactona fechado, no fabrico de um medicamento para o tratamento do cancro do cólon

Legal Events

Date Code Title Description
8364 No opposition during term of opposition